Economic Benefits of a Routine Second Dose of Combined Measles, Mumps and Rubella Vaccine in Canada

Economic Benefits of a Routine Second Dose of Combined Measles, Mumps and Rubella Vaccine in Canada

OBJECTIVE: To evaluate the potential economic benefits of a program for a second routine dose of combined measles, mumps and rubella (MMR) vaccine, administered to children in Canada.

Saved in:

Bibliographic Details
Main Authors:	Marc Rivière, Roma Tretiak, Carey Levinton, Catherine Fitzsimon, Caroline Leclerc
Format:	Article
Language:	English
Published:	Wiley 1997-01-01
Series:	Canadian Journal of Infectious Diseases
Online Access:	http://dx.doi.org/10.1155/1997/215175
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Domestic Tetravaccine (Measles-Rubella-Mumps) – Immunization of Premature Babies
by: V. V. Semerikov, et al.
Published: (2022-09-01)

Improving the Epidemiological Surveillance of Measles, Rubella and Mumps in the Russian Federation
Published: (2023-01-01)

Collective Immunity to the Measles, Mumps, and Rubella Viruses in the Kyrgyz Population
by: Anna Yurievna Popova, et al.
Published: (2025-02-01)

Gianotti–Crosti Syndrome Following Measles, Mumps, and Rubella Vaccination
by: Reena Rai, et al.
Published: (2025-01-01)

STATE OF MEASLES, RUBELLA AND MUMPS IN THE SARATOV REGION IN 2001—2013 YEARS
by: T. N. Buchkova, et al.
Published: (2015-08-01)

Mumps antibody in the Thai population 17 years after the universal measles mumps rubella vaccination program
by: Varisara Ngaovithunvong, et al.
Published: (2016-08-01)

Timing of Measles, Mumps, and Rubella Vaccination: Secondary Outcomes from an Immunological Survey
by: Jana Zibolenová, et al.
Published: (2025-04-01)

Safety of antibodies to measles, mumps, rubella and diphtheria in patients with juvenile idiopathic arthritis
by: I. V. Fridman, et al.
Published: (2021-07-01)

MEASLES-MUMPS-RUBELLA VACCINATION IN A PAEDIATRIC TRANSPLANT PATIENT USING EVEROLIMUS
by: Aybüke Kaçır, et al.
Published: (2025-01-01)

Herd Immunity to the Measles, Mumps and Rubella Viruses Among the Belgradian Population in May, 2024
by: Anna Y. Popova, et al.
Published: (2025-06-01)

Characteristics of the epidemic process of measles, rubella and mumps in Moscow and assessment of their seroprevalence at the present stage
by: Yana V. Simakova, et al.
Published: (2025-04-01)

Persistence in epidemic metapopulations: quantifying the rescue effects for measles, mumps, rubella and whooping cough.
by: C Jessica E Metcalf, et al.
Published: (2013-01-01)

A review of safety and immunogenicity of a novel measles, mumps, rubella (MMR) vaccine
by: Nitin Shah, et al.
Published: (2024-12-01)

Comparative analysis of immunogenicity between first-dose measles-mumps-rubella (MMR) vaccine administration and combined MMR-rotavirus vaccination
by: Xue-Feng Liang, et al.
Published: (2025-12-01)

Seroprevalence of Measles, Rubella and Mumps Antibodies in Foreign Citizens Registered in Moscow Region (Labour Migrants)
by: T. A. Semenenko, et al.
Published: (2017-06-01)

Humoral Immunity to Measles, Mumps, Rubella, Diphtheria, Tetanus and Pertussis After Cancer Treatment in Children
by: Susanna Sundell, et al.
Published: (2025-05-01)

Reactogenicity and immunogenicity of a new measles-mumps-rubella vaccine containing RIT 4385 mumps virus strain in healthy Turkish children
by: G Kanra, et al.
Published: (2000-10-01)

Measles-mumps-rubella-vaccination at 6 months of age induces measles-specific T cell responses: a randomized controlled trial
by: Søren Buus, et al.
Published: (2025-03-01)

Impact of Measles, Mumps, and Rubella Vaccination on Hospitalizations and Human Capital: Evidence from Copenhagen School Health Records
by: Onur Altindag, et al.
Published: (2025-03-01)

Seroprevalence of Measles-, Mumps-, and Rubella-Specific Antibodies in Future Healthcare Workers in Serbia: A Cross-Sectional Study
by: Ana Banko, et al.
Published: (2025-06-01)

The Oncogenic Human Papillomavirus Involvement as a Risk Factor of Measles, Mumps, and Rubella Vaccine Immunotherapy Failure in Anogenital Warts
by: Achdiat PA, et al.
Published: (2025-01-01)

Serological status of measles, mumps, and rubella antibodies in HIV-positive women of childbearing age at a referral hospital in Iran
by: Sara Ghaderkhani, et al.
Published: (2025-04-01)

Clinical and laboratorial aspects of aseptic meningitis associated with MMR (measles-mumps-rubella) vaccine at a referral hospital in the State of Bahia
by: Rita Lucena
Published: (2002-03-01)

Regional Meeting on Measles and Rubella
by: Editorial article
Published: (2018-04-01)

Measles， rubella， and mumps antibody seroprevalence among the children aged 18 years and younger in Karamay City， Xinjiang Uygur Autonomous Region
by: WU Meili, et al.
Published: (2025-03-01)

Revaccination and its efficacy against hepatitis B virus, measles, mumps, and rubella in children after allogeneic hematopoietic stem cell transplantation
by: Jiaoyang Cai, et al.
Published: (2025-03-01)

Impact of vaccination strategy adjustments on antibody levels against measles, rubella, mumps, and varicella in China: a single-center serological survey
by: Zhixin Geng, et al.
Published: (2025-08-01)

The Health and Economic Benefits of United States Investments in Measles and Rubella Control and Elimination
by: Kimberly M. Thompson
Published: (2024-10-01)

THE RESULTS OF STUDY OF THE LEVELS OF SPECIFIC ANTIBODIES TO THE COMBINED INJECTION VACCINES AGAINST INFLUENZA, MEASLES, RUBELLA AND MUMPS AND DT IN CHILDREN WITH CHRONIC PHYSICAL ILLNESS
by: S. M. Haritе, et al.
Published: (2015-08-01)

Persistence of major socio-economic inequalities in childhood measles–mumps–rubella vaccination coverage and timeliness under vaccination mandates, France, 2015 to 2024
by: Pierre Verger
Published: (2025-04-01)

Lessons for sustaining the elimination of measles, rubella, and congenital rubella syndrome in the Caribbean
by: Tracy Evans-Gilbert, et al.
Published: (2024-12-01)

Immunological Protection Against Vaccine-Preventable Infections (Hepatitis B, Measles, Rubella, Mumps, Diphtheria, Tetanus) of Russian and Foreign Students: A Simultaneous Study
by: Diana V. Sutovskaya, et al.
Published: (2020-02-01)

A Comparative Prospective Study to Assess Efficacy of Intralesional MMR (Measles, Mumps, Rubella) Vaccine and Intralesional Vitamin D3 in Treatment of Nongenital Warts
by: Bibisha Baaniya, et al.
Published: (2025-05-01)

A Randomised Single-Blind Controlled Trial Comparing Efficacy of Intralesional Vitamin D Injection and MMR (Measles, Mumps, Rubella) Vaccine in Treatment of Warts
by: Sushil Singh, et al.
Published: (2025-05-01)

Standards for the Epidemiological Investigation of Measles and Rubella Foci
by: O. V. Tsvirkun, et al.
Published: (2023-05-01)

Slow progress in measles and rubella elimination in Italy
by: Giovanna Adamo, et al.
Published: (2016-09-01)

A Comparative Study of the Efficacy of Intralesional Measles Mumps Rubella (MMR) Vaccine and Auto Implantation for the Treatment of Periungual and Palmoplantar Warts: A Randomized Controlled Trial
by: Ravindra Abusaria, et al.
Published: (2024-08-01)

Measles, mumps and rubella vaccination coverage in capitals and interior region municipalities of Northeast Brazil: a household survey in a cohort of children born in 2017 and 2018
by: Adjoane Mauricio Silva Maciel, et al.
Published: (2024-12-01)

Impact of the COVID-19 pandemic on timeliness and equity of measles, mumps and rubella vaccinations in North East London: a longitudinal study using electronic health records
by: Carol Dezateux, et al.
Published: (2022-12-01)

Immunogenicity and safety of measles-mumps-rubella vaccine delivered by the aerosol, intradermal and intramuscular routes in previously vaccinated young adults: a randomized controlled trial protocol.
by: Sumanta Saha, et al.
Published: (2025-01-01)